Truist analyst David MacDonald raised the firm’s price target on Humana (HUM) to $270 from $220 and keeps a Hold rating on the shares. The company reported solid Q1 results, with medical care ratio and adjusted earnings better than estimates, while core utilization trends were broadly in line or better, and the guidance for FY26 was reaffirmed across the board, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUM:
- Humana price target raised to $262 from $195 at UBS
- Humana price target raised to $269 from $252 at Guggenheim
- Humana Kept at Hold as Analyst Raises Price Target to $267 Amid Margin-Rebuild Focus and Uncertain Medical Cost Trends
- Humana price target raised to $180 from $176 at Barclays
- Humana Charts Cautious Path in Earnings Call